LDS/Medical Tests/IMMray, PanCan-d Test for Early Detection of Pancreatic Cancer

IMMray, PanCan-d Test for Early Detection of Pancreatic Cancer

Pancreatic cancer is the third leading cause of cancer-related death in both men and women, with most cases diagnosed at an advanced stage. The overall 5-year survival rate for pancreatic cancer is less than 20% when detected at stage II–IV, whereas it exceeds 80% if identified at stage I. This underscores the critical importance of early detection.

The IMMray™ PanCan-d test is the first blood-based assay specifically designed for pancreatic cancer detection. It integrates an 8-plex serum biomarker signature with CA19-9, analyzed using a proprietary immunoassay platform. Clinical studies have shown 92% sensitivity and 99% specificity in detecting pancreatic cancer, including early-stage disease.

The test is also valuable for individuals at increased hereditary risk of pancreatic cancer, including those with germline mutations in genes such as BRCA1, BRCA2, KRAS, PALB2, ATM, MLH1, MSH2, STK11, PRSS1, and CDKN2A. By identifying disease at an earlier stage, the IMMray™ PanCan-d test may improve prognosis and expand treatment options.

  • Enables earlier detection of pancreatic cancer in at-risk individuals
  • Improves patient prognosis by allowing earlier diagnosis and intervention
  • May complement imaging, CA19-9, and genetic testing in comprehensive risk assessment

Positive/High Risk Score: Indicates a high probability of pancreatic cancer; patients should undergo confirmatory imaging (e.g., MRI, CT) and further clinical evaluation.

Negative/Low Risk Score: Suggests low probability of pancreatic cancer; continued surveillance recommended in high-risk individuals.

Not available. Usually reported qualitatively as positive, negative, or borderline

Multiplex immunoassay (8-plex biomarker panel + CA19-9) with diagnostic algorithm.

Whole blood, EDTA.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: 30 days
Amylase, Lipase, ALP, CA19-9, comprehensive metabolic panel, pancreatic biopsy, CA125, insulin, elastase, KRAS gene mutation analysis.
3 to 5 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login